14 Panda Cubs Celebrate First 100 Days

Nov. 4 (Bloomberg) -- On "Hot Shots," Bloomberg's Mark Crumpton reports on today's most compelling images. (Source: Bloomberg)

Merck KgaA, Pfizer Cancer Drug to Cost $13,000 a Month
08:41 - Pfizer and Merck KGaA’s cancer immunotherapy won approval from U.S. regulators for patients with a rare form of skin cancer, and the companies plan to sell the drug for $13,000 a month. Merck KgaA CEO Stegfan Oschmann speaks on "Bloomberg Daybreak Europe." (Source: Bloomberg)
  • Aviva's Diebel Sees No Macro Impact From Healthcare Bill
  • Italy Junior Minister Sees Brexit as EU Opportunity
  • French Presidential Race Takes an Inflammatory Turn